Search research articles
Contact Us
Filters
Showing results (11-20 of 51) with videos related to
Page
of 6
Sort By:
Schizophrenia Bulletin Open
|
August 15, 2024
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment
Dragana Bugarski-Kirola, Istvan Bitter, I-Yuan Liu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 22, 2007
Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Istvan Bitter, Tamas Treuer, Yulia Dyachkova, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
February 7, 2016
A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe
Pierre Baumann, Marie Spies, Hans-Jürgen Möller, et al.
The Journal of Physical Chemistry. B
|
June 6, 2007
Complexation of phenols by calix[4]arene Diethers in a low-permittivity solvent. Self-switched complexation by 25,27-Dibenzyloxycalix[4]arene
Sandor Kunsagi-Maté, Kornélia Szabó, Bernard Desbat, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 1, 2019
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
Filippo Corponi, Chiara Fabbri, Istvan Bitter, et al.
Current Therapeutic Research, Clinical and Experimental
|
June 18, 2014
Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study
Valentinas Maciulis, Istvan Bitter, Raimundas Milasiunas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 1, 2012
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial
Silvana Galderisi, Armida Mucci, Istvan Bitter, et al.
International Journal of Psychiatry in Clinical Practice
|
June 19, 2014
Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO)
Tamás Treuer, Martin Anders, Istvan Bitter, et al.
Human Psychopharmacology
|
October 31, 2002
Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study dagger
Jean Pierre Lepine, Carlo Altamura, Marc Ansseau, et al.
The Journal of Clinical Psychiatry
|
August 10, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)
Jan Volavka, Pal Czobor, Eske M Derks, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 51) with videos related to
Sort By:
Page
of 6
Schizophrenia Bulletin Open
|
August 15, 2024
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment
Dragana Bugarski-Kirola, Istvan Bitter, I-Yuan Liu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 22, 2007
Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Istvan Bitter, Tamas Treuer, Yulia Dyachkova, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
February 7, 2016
A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe
Pierre Baumann, Marie Spies, Hans-Jürgen Möller, et al.
The Journal of Physical Chemistry. B
|
June 6, 2007
Complexation of phenols by calix[4]arene Diethers in a low-permittivity solvent. Self-switched complexation by 25,27-Dibenzyloxycalix[4]arene
Sandor Kunsagi-Maté, Kornélia Szabó, Bernard Desbat, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 1, 2019
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
Filippo Corponi, Chiara Fabbri, Istvan Bitter, et al.
Current Therapeutic Research, Clinical and Experimental
|
June 18, 2014
Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study
Valentinas Maciulis, Istvan Bitter, Raimundas Milasiunas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 1, 2012
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial
Silvana Galderisi, Armida Mucci, Istvan Bitter, et al.
International Journal of Psychiatry in Clinical Practice
|
June 19, 2014
Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO)
Tamás Treuer, Martin Anders, Istvan Bitter, et al.
Human Psychopharmacology
|
October 31, 2002
Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study dagger
Jean Pierre Lepine, Carlo Altamura, Marc Ansseau, et al.
The Journal of Clinical Psychiatry
|
August 10, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)
Jan Volavka, Pal Czobor, Eske M Derks, et al.
Page
of 6